Lorecivivint is a novel small-molecule inhibitor that modulates the Wnt pathway through CLK/DYRK kinase.It is administered through intra-articular injection for the treatment of knee osteoarthritis.Phase Ⅲ clinical trials for lorecivivint are currently underway in the United States.Completed clinical trials have demonstrated that lorecivivint has good safety and tolerability,with significant efficacy in pain relief and improvement of knee joint function.Long-term treatment has shown potential in improving joint structure,making it a promising disease-modifying osteoarthritis drug.This article provides an overview of the basic information,mechanism of action,pharmacokinetics and clinical research progress of lorecivivint.
lorecivivintWnt pathwayCLK/DYRK kinase inhibitorsknee osteoarthritisdisease-modifying osteoarthritis drug
NETL
NSTL
万方数据
